Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 6 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Gh Research Ireland Limited has 11 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 11 distinct examiners and 6 distinct art units, so examiner distribution is broader than art-unit distribution. Multiple examiners therefore appear within the identified units, creating a portfolio that requires both matter-level and unit-level coordination.
JACKSON, SHAWQUIA is the busiest examiner, with 1 pending matter. No listed examiner carries more than that assignment, which makes a centralized examiner strategy unsuitable as the primary management model.
Counsel should maintain a shared scientific position across the portfolio while tracking amendments, cited references, interviews, and response deadlines separately. The art-unit grouping can support consistency in technical arguments, but the examiner spread calls for individualized prosecution plans.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (9%) |
| §103 only | 3 (27%) |
| Double-patenting + other | 6 (55%) |
| Multi-statute (no §101) | 1 (9%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.4% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.5% |
| KIM, SEONG JONG | 1 | 25.0% | +0.0% |
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.3% |
| AGGARWAL, SAHIL CHANDER | 1 | 66.7% | +0.0% |
| SCHMIDT, IZABELA MARIA | 1 | 65.7% | +42.7% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
| LEE, CHIHYI NMN | 1 | 33.3% | +61.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18373903 | TREATMENT OF MENTAL DISORDERS | DEKARSKE, MADELINE MCGUIRE | 60d overdue |
| 18851346 | 5-MEO-DMT FOR USE IN THE TREATMENT OF SLEEP DISTURBANCE | COUGHLIN, MATTHEW P | — |
| 18851301 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF SOCIAL/EMOTIONAL WITHDRAWAL OR DETACHMENT | KIM, SEONG JONG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18851294 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF ANXIETY | WHITE, DAWANNA SHAR-DAY | — |
| 18851346 | 5-MEO-DMT FOR USE IN THE TREATMENT OF SLEEP DISTURBANCE | COUGHLIN, MATTHEW P | — |
| 18851349 | 5-MEO-DMT FOR USE IN THE TREATMENT OF SLEEP DISTURBANCE | ROZOF, TIMOTHY R | — |
| 18850362 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF PSYCHOMOTOR RETARDATION | SCHMIDT, IZABELA MARIA | — |
| 18850348 | TREATMENT OF ANXIETY | RODRIGUEZ, RAYNA B | — |
| 18850370 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF SOCIAL/EMOTIONAL WITHDRAWAL OR DETACHMENT | CHANDRAKUMAR, NIZAL S | — |
| 18675614 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT) FOR TREATING DEPRESSION | LEE, CHIHYI NMN | — |
| Art Unit | Apps |
|---|---|
| 1626 | 2 |
| 1621 | 2 |
| 1628 | 2 |
| 1627 | 1 |
| 1625 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18920063 | ORGANIC COMPOUND SALTS | JACKSON, SHAWQUIA | 1626 | §103DP | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18851294 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF ANXIETY | WHITE, DAWANNA SHAR-DAY | 1627 | §102§103DP | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18851346 | 5-MEO-DMT FOR USE IN THE TREATMENT OF SLEEP DISTURBANCE | COUGHLIN, MATTHEW P | 1626 | §101§102§112DP | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18851301 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF SOCIAL/EMOTIONAL WITHDRAWAL OR DETACHMENT | KIM, SEONG JONG | 1621 | §102§103§112DP | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18851349 | 5-MEO-DMT FOR USE IN THE TREATMENT OF SLEEP DISTURBANCE | ROZOF, TIMOTHY R | 1625 | §102DP | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18851343 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF BIPOLAR DISORDER | AGGARWAL, SAHIL CHANDER | — | §103Other | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18850362 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF PSYCHOMOTOR RETARDATION | SCHMIDT, IZABELA MARIA | 1621 | §102§103DP | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18850348 | TREATMENT OF ANXIETY | RODRIGUEZ, RAYNA B | 1628 | §102§103DP | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18850370 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF SOCIAL/EMOTIONAL WITHDRAWAL OR DETACHMENT | CHANDRAKUMAR, NIZAL S | — | §103Other | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18675614 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT) FOR TREATING DEPRESSION | LEE, CHIHYI NMN | 1628 | §103Other | Final Rejection | — | Pending | May 28, 2024 |
| 18373903 | TREATMENT OF MENTAL DISORDERS | DEKARSKE, MADELINE MCGUIRE | 1622 | §102§103Other | Final Rejection | 60d overdue | Pending | Sep 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGh Research Ireland Limited has 11 pending office actions as of October 2026, spread across 6 art units and 11 examiners.
Shawquia Jackson has the most, with 1 of Gh Research Ireland Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
